Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck

Head and Neck

Volumn 30, Issue 3, 2008, Pages 281-288

  Spencer, Sharon A ^a   Harris, Jonathan ^b   Wheeler, Richard H ^c   Machtay, Mitchell ^d   Schultz, Christopher ^e   Spanos, William ^f   Rotman, Marvin ^g   Meredith, Ruby ^a   Ang, Kie Kian ^h  

^a The University of Alabama at Birmingham   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f University of Louisville School of Medicine   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiation; Late effects; Recurrent head and neck; Reirradiation; Squamous cell carcinoma

Indexed keywords

FLUOROURACIL; HYDROXYUREA;

ACUTE TOXICITY; ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; FEMALE; HEAD AND NECK CANCER; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECURRENT CANCER; SCORING SYSTEM; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RETREATMENT; SURVIVAL RATE;

EID: 41649118634     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20697     Document Type: Article

References (30)

1. Jacob C, Layman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-263.
2. Forastiere A, Metch B, Schuller D, et al. Randomize comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-1251.
3. Spencer SA, Harris J, Wheeler RH, et al. RTOG 9610: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001;51:1299-1304.
4. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980. pp 163-178.
5. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
6. Wang CC. Reirradiation of recurrent nasopharyngeal carcinoma; treatment techniques and results. Int J Radiat Oncol Biol Phys 1987;13:953-956.
7. Stevens KR Jr, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 1994;29:687-698.
8. Lee AWM, Foo W, Law SCK, et al. Reirradiation for recurrent nasopharyngeal carcinoma: factors affecting the therapeutic ratio and ways for improvement. Int J Radiat Oncol Biol Phys 1997;38:43-52.
9. Emami B, Marks JE, Perez CA, Nussbaum GH, Leybovich L, Von Gerichten D. Interstitial thermoradiotherapy in the treatment of recurrent/residual malignant tumors. Am J Clin Oncol 1984;7:699-704.
10. Puthawala A, Syed N, Gamie S, Chen YJ, Londrc A, Nixon V. Interstitial low-dose-rate brachytherapy as a salvage treatment for recurrent head and neck cancer: long-term results. Int J Radiat Oncol Biol Phys 2001;51:354-362.
11. Levendag PC, Meeuwis CA, Visser AG. Reirradiation of recurrent head and neck cancers: external and/or interstitial radiation therapy. Radiother Oncol 1992;1:6-15.
12. Neider C. Tissue tolerance to reirradiation. Sem Radiat Oncol 2001;10:200-209.
13. Vokes EE, Panje WR, Schilsky RL, et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol 1989;7:761-776.
14. Pryzant RM, Wendt CD, Delclos L, Peters LJ. Re-treatment of nasopharyngeal carcinoma in 53 patients. Int J Radiat Oncol Biol Phys 1992;22:941-947.
15. Yan JH, Hu YH, Gu XZ. Radiation therapy of recurrent nasopharyngeal carcinoma. Report on 219 patients. Acta Radiol Oncol 1983;22:23-28.
16. Fu KK, Newman H, Phillips TL. Treatment of locally recurrent carcinoma of the nasopharynx. Radiology 1975;117:425-431.
17. Wang CC, McIntyre J. Re-irradiation of laryngeal carcinoma - techniques and results. Int J Radiat Oncol Biol Phys 1993;26:783-785.
18. Lavendag P, Meeuwis C, Visser A. Reirradiation of recurrent head and neck cancers. Radiother Oncol 1992;23:115-121.
19. Saroja KR, Hendrickson FR, Cohen L, Mansell J, Lennox A. Re-irradiation of locally recurrent tumors with fast neutrons. Int J Radiat Oncol Biol Phys 1988;15:115-121.
20. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395); and intergroup trial of Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567.
21. Genet D, Cupissol D, Calais G, et al. Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol 2004;27:474-476.
22. Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Rad Oncol Biol Phys 2006;64:382-391.
23. Spencer SA, Wheeler RH, Peters GE, et al. Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. Am J Clin Oncol 1999;22:1-5.
24. Spencer SA, Wheeler R, Peters G, et al. Phase I trial of combined chemotherapy and re-irradiation for recurrent unresectable head and neck cancer. Head Neck 2003;25:118-122.
25. DeCrevoisier R, Bourhis J, Domenge C, et al. Full dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998;16:3556-3652.
26. DeCrevoisier R, Domenge C, Wibault P, et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 2001;91:2071-2076.
27. Milano MT, Vokes EE, Salama JK, et al. Twice-daily re-irradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys 2005;61:1096-1106.
28. Janot F, deRaucourt D, Castaing M, et al. Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: a randomized trial. 2006 Annual meeting and research workshop on the biology, prevention and treatment of head and neck cancer. August 17-20, Chicago, IL.
29. Machtay M, Rosenthal DI, Chalian AA, et al. Pilot study of postoperative reirradiation, chemotherapy and amifostine after surgical salvage for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2004;59:72-77.
30. Horwitz EM, Harris J, Langer CJ, et al. Concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): update of RTOG 9911. J Clin Oncol 2005;23:5577 (ASCO Proceedings Abstract).